NasdaqGS:ARQTBiotechs
Assessing Arcutis Biotherapeutics (ARQT) Valuation After New Genital Psoriasis Clinical Guidance Publication
Arcutis Biotherapeutics (ARQT) is back in focus after supporting a new American Journal of Clinical Dermatology manuscript that provides practical guidance on diagnosing and managing genital psoriasis across age groups, highlighting the company’s role in clinician education.
See our latest analysis for Arcutis Biotherapeutics.
Despite attention on the new genital psoriasis guidance and recent restricted stock unit grants, Arcutis Biotherapeutics’ share price, at US$21.23, has fallen sharply...